Filtered By:
Source: Circulation
Education: Study

This page shows you your search results in order of date. This is page number 14.

Order by Relevance | Date

Total 422 results found since Jan 2013.

Response by Mehra and Colombo to Letter Regarding Article, "Comprehensive Analysis of Stroke in the Long-Term Cohort of the MOMENTUM 3 Study: A Randomized Controlled Trial of the Heartmate 3 Versus the Heartmate II Cardiac Pump".
PMID: 31329492 [PubMed - in process]
Source: Circulation - July 22, 2019 Category: Cardiology Authors: Mehra MR, Colombo PC Tags: Circulation Source Type: research

Letter by Consolo and Pappalardo Regarding Article, "Comprehensive Analysis of Stroke in the Long-Term Cohort of the MOMENTUM 3 Study: A Randomized Controlled Trial of the Heartmate 3 Versus the Heartmate II Cardiac Pump".
PMID: 31329490 [PubMed - in process]
Source: Circulation - July 22, 2019 Category: Cardiology Authors: Consolo F, Pappalardo F Tags: Circulation Source Type: research

Impact of ADCY9 Genotype on Response to Anacetrapib.
CONCLUSIONS: The REVEAL trial is the single largest study to date evaluating the ADCY9 pharmacogenetic interaction. It provides no support for the hypothesis that ADCY9 genotype is materially relevant to the clinical effects of the CETP inhibitor anacetrapib. The ongoing dal-GenE study will provide direct evidence as to whether there is any specific pharmacogenetic interaction with dalcetrapib. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov Unique Identifier: NCT01252953; URL: http://www.isrctn.com Unique Identifier: ISRCTN48678192; URL: https://www.clinicaltrialsregister.eu Unique Identifier: 2010-0...
Source: Circulation - July 22, 2019 Category: Cardiology Authors: Hopewell JC, Ibrahim M, Hill M, Shaw PM, Braunwald E, Blaustein RO, Bowman L, Landray MJ, Sabatine MS, Collins R, HPS3/TIMI55 - REVEAL Collaborative Group Tags: Circulation Source Type: research

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial.
CONCLUSIONS: Canagliflozin significantly reduced major cardiovascular events, as well as kidney failure, in patients with type 2 diabetes and chronic kidney disease, including in participants who did not have prior cardiovascular disease. CLINICAL TRIAL REGISTRATION: URL: https://ClinicalTrials.gov Unique identifier: NCT02065791. PMID: 31291786 [PubMed - as supplied by publisher]
Source: Circulation - July 10, 2019 Category: Cardiology Authors: Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler DC, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner BM, Perkov Tags: Circulation Source Type: research

Use of Genetic Variants Related to Antihypertensive Drugs to Inform on Efficacy and Side Effects.
CONCLUSIONS: Genetic variants can be used to explore the efficacy and side effects of antihypertensive medications. The identified potential effect of nondihydropyridine CCBs on diverticulosis risk could have clinical implications and warrants further investigation. PMID: 31234639 [PubMed - as supplied by publisher]
Source: Circulation - June 24, 2019 Category: Cardiology Authors: Gill D, Georgakis MK, Koskeridis F, Jiang L, Feng Q, Wei WQ, Theodoratou E, Elliott P, Denny JC, Malik R, Evangelou E, Dehghan A, Dichgans M, Tzoulaki I Tags: Circulation Source Type: research

Novel Drug Targets for Ischemic Stroke Identified Through Mendelian Randomization Analysis of the Blood Proteome.
CONCLUSIONS: Through a systematic MR screen of the circulating proteome, causal roles for five established and two novel biomarkers for ischemic stroke were identified. Side-effect profiles were characterized to help inform drug target prioritization. In particular, SCARA5 represents a promising target for treatment of cardioembolic stroke with no predicted adverse side-effects. PMID: 31208196 [PubMed - as supplied by publisher]
Source: Circulation - June 17, 2019 Category: Cardiology Authors: Chong M, Sjaarda J, Pigeyre M, Mohammadi-Shemirani P, Lali R, Shoamanesh A, Gerstein HC, Paré G Tags: Circulation Source Type: research

Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association.
and Stroke Nursing; Council on Clinical Cardiology; and Stroke Council Abstract As early and effective antiretroviral therapy has become more widespread, HIV has transitioned from a progressive, fatal disease to a chronic, manageable disease marked by elevated risk of chronic comorbid diseases, including cardiovascular diseases (CVDs). Rates of myocardial infarction, heart failure, stroke, and other CVD manifestations, including pulmonary hypertension and sudden cardiac death, are significantly higher for people living with HIV than for uninfected control subjects, even in the setting of HIV viral suppression with...
Source: Circulation - June 2, 2019 Category: Cardiology Authors: Feinstein MJ, Hsue PY, Benjamin LA, Bloomfield GS, Currier JS, Freiberg MS, Grinspoon SK, Levin J, Longenecker CT, Post WS, American Heart Association Prevention Science Committee of the Council on Epidemiology and Prevention and Council on Cardiovascular Tags: Circulation Source Type: research

High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study.
CONCLUSIONS: Elevated hs-TnI is strongly associated with increased global CVD incidence in the general population independent of traditional risk factors. hs-TnI and high-sensitivity troponin T provide complementary rather than redundant information. PMID: 31030544 [PubMed - as supplied by publisher]
Source: Circulation - April 28, 2019 Category: Cardiology Authors: Jia X, Sun W, Hoogeveen RC, Nambi V, Matsushita K, Folsom AR, Heiss G, Couper DJ, Solomon SD, Boerwinkle E, Shah A, Selvin E, de Lemos JA, Ballantyne CM Tags: Circulation Source Type: research

Biomarkers of Dietary Omega-6 Fatty Acids and Incident Cardiovascular Disease and Mortality: An Individual-Level Pooled Analysis of 30 Cohort Studies.
CONCLUSIONS: In pooled global analyses, higher in vivo circulating and tissue levels of LA and possibly AA were associated with lower risk of major cardiovascular events. These results support a favorable role for LA in CVD prevention. PMID: 30971107 [PubMed - as supplied by publisher]
Source: Circulation - April 10, 2019 Category: Cardiology Authors: Marklund M, Wu JHY, Imamura F, Del Gobbo LC, Fretts A, de Goede J, Shi P, Tintle N, Wennberg M, Aslibekyan S, Chen TA, de Oliveira Otto MC, Hirakawa Y, Eriksen HH, Kröger J, Laguzzi F, Lankinen M, Murphy RA, Prem K, Samieri C, Virtanen J, Wood AC, Wong K Tags: Circulation Source Type: research

Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction: A Sub-analysis From DECLARE TIMI-58 Trial.
CONCLUSIONS: Patients with T2DM and prior MI are at high risk of MACE and CV death/HHF. Dapagliflozin appears to robustly reduce the risk of both composite outcomes in these patients. Future studies should aim to confirm the large clinical benefits with SGLT2i we observed in patients with prior MI. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov Unique Identifier: NCT01730534. PMID: 30882239 [PubMed - as supplied by publisher]
Source: Circulation - March 17, 2019 Category: Cardiology Authors: Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Nicolau JC, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Wiviott SD Tags: Circulation Source Type: research

Device-Detected Atrial Fibrillation: Evidencing the Knowledge Gap.
Abstract Stroke is a devastating complication of atrial fibrillation (AF) the odds of which can be reduced by use of oral anticoagulation based on the stroke risk score.1,2 Patients with asymptomatic clinical AF have a similar stroke risk as patients with symptomatic clinical AF.3 Thus far, electrocardiographic- (ECG) or Holter monitor-detected AF is a prerequisite before use of oral anticoagulation,1,2 because the guideline recommendations are based on studies that included only ECG- or Holter-detected AF ('clinical' AF).1,2 In the past decades increasing number of cardiac implantable electronic devices (CIED) ha...
Source: Circulation - March 16, 2019 Category: Cardiology Authors: Mulder BA, van Gelder IC, Rienstra M Tags: Circulation Source Type: research

Practice Variation in Anticoagulation Prescription and Outcomes after Device-Detected Atrial Fibrillation: Insights from the Veterans Health Administration.
CONCLUSIONS: Among Veterans with CIEDs, device-detected AF is common. There is large practice variation in 90-day OAC initiation after new device-detected AF with low rates of treatment overall, even for episodes >24 hours. The strongest association of OAC with reduction in stroke was observed after device-detected AF >24 hours. Randomized trials are needed to confirm these observational findings. PMID: 30880434 [PubMed - as supplied by publisher]
Source: Circulation - March 16, 2019 Category: Cardiology Authors: Perino AC, Fan J, Askari M, Heidenreich PA, Keung E, Raitt MH, Piccini JP, Ziegler PD, Turakhia MP Tags: Circulation Source Type: research

Water Pipe (Hookah) Smoking and Cardiovascular Disease Risk: A Scientific Statement From the American Heart Association.
The objectives of this statement are to describe the design and operation of water pipes and their use patterns, to identify harmful and potentially harmful constituents in water pipe smoke, to document the cardiovascular risks of water pipe use, to review current approaches to water pipe smoking cessation, and to offer guidance to healthcare providers for the identification and treatment of individuals who smoke tobacco using water pipes. PMID: 30845826 [PubMed - as supplied by publisher]
Source: Circulation - March 7, 2019 Category: Cardiology Authors: Bhatnagar A, Maziak W, Eissenberg T, Ward KD, Thurston G, King BA, Sutfin EL, Cobb CO, Griffiths M, Goldstein LB, Rezk-Hanna M, American Heart Association Behavioral Change for Improving Health Factors Committee of the Council on Lifestyle and Cardiometab Tags: Circulation Source Type: research

Substantial Cardiovascular Morbidity in Adults with Lower-Complexity Congenital Heart Disease.
CONCLUSIONS: Individuals with lower-complexity ACHD had higher burden of adverse cardiovascular events relative to the general population that was unaccounted for by conventional cardiovascular risk factors. These findings highlight the need for closer surveillance of patients with mild to moderate ACHD and further investigation into management and mechanisms of cardiovascular risk unique to this growing population of high-risk adults. PMID: 30813762 [PubMed - as supplied by publisher]
Source: Circulation - February 27, 2019 Category: Cardiology Authors: Saha P, Potiny P, Rigdon J, Morello M, Tcheandjieu C, Romfh A, Fernandes SM, McElhinney DB, Bernstein D, Lui GK, Shaw GM, Ingelsson E, Priest JR Tags: Circulation Source Type: research

Randomized Trial Evaluating Percutaneous Coronary Intervention for the Treatment of Chronic Total Occlusion: The DECISION-CTO Trial.
CONCLUSIONS: CTO-PCI was feasible with high success rates. There was no difference in the incidence of major adverse cardiovascular events with CTO PCI vs. no CTO-PCI, but the study was limited by low power for clinical endpoints and high crossover rates between groups. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov Unique Identifier: NCT01075051. PMID: 30813758 [PubMed - as supplied by publisher]
Source: Circulation - February 27, 2019 Category: Cardiology Authors: Lee SW, Lee PH, Ahn JM, Park DW, Yun SC, Han S, Kang H, Kang SJ, Kim YH, Lee CW, Park SW, Hur SH, Rha SW, Her SH, Choi SW, Lee BK, Lee NH, Lee JY, Cheong SS, Kim MH, Ahn YK, Lim SW, Lee SG, Hiremath S, Santoso T, Udayachalerm W, Cheng JJ, Cohen DJ, Murama Tags: Circulation Source Type: research